Literature DB >> 17560610

Reduction of post-surgical adhesion formation with tranilast.

Kevin Cooper1, Janel Young, Scott Wadsworth, Helen Cui, Gere S diZerega, Kathleen E Rodgers.   

Abstract

BACKGROUND: Preclinical studies using the rabbit sidewall and double uterine horn models were used to assess time and dose response of tranilast delivered via subcutaneous pump, p.o., or as an intraperitoneal bolus in viscoelastic gels as well as an intraperitoneal biodegradable poly(p-dioxanone) fiber in reducing adhesions compared to vehicle controls.
MATERIALS AND METHODS: New Zealand white rabbits underwent laparotomy followed by: 1) uterine horn abrasion and peripheral devascularization or 2) cecal abrasion and sidewall deperitonealization. Tranilast treatment using various vehicles and dosages was compared to vehicle alone versus no treatment. Animals were euthanized after 7 to 21 days. Adhesion formation was assessed by two independent observers.
RESULTS: There were reductions in adhesion formation when drug was delivered topically, but oral drug alone was not effective. When tranilast was given preoperatively, oral drug added to the adhesion reduction of intraperitoneal administered drug. Tranilast in a viscoelastic carrier as well as in a biodegradable fiber was effective at reducing adhesions in the double uterine horn model. The slow release of tranilast from a biodegradable rod produced overall the best results. There were no safety issues.
CONCLUSION: Tranilast was effective in reducing adhesions when given in a variety of vehicles in different rabbit models of adhesion formation. Overall, the sustained intraperitoneal delivery of tranilast from biodegradable fibers was the most suitable for clinical testing.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17560610     DOI: 10.1016/j.jss.2006.05.044

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  3 in total

1.  Fibrin-targeted block copolymers for the prevention of postsurgical adhesions.

Authors:  John M Medley; Eugene Kaplan; Helieh S Oz; Sharath C Sundararaj; David A Puleo; Thomas D Dziubla
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2011-06-21       Impact factor: 3.368

Review 2.  Pharmacological treatment options for mast cell activation disease.

Authors:  Gerhard J Molderings; Britta Haenisch; Stefan Brettner; Jürgen Homann; Markus Menzen; Franz Ludwig Dumoulin; Jens Panse; Joseph Butterfield; Lawrence B Afrin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-04-30       Impact factor: 3.000

3.  PuraStat RADA16 Self-Assembling Peptide Reduces Postoperative Abdominal Adhesion Formation in a Rabbit Cecal Sidewall Injury Model.

Authors:  Eun Seok Gil; Elton Aleksi; Lisa Spirio
Journal:  Front Bioeng Biotechnol       Date:  2021-12-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.